A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia
Status:
Completed
Trial end date:
2005-08-30
Target enrollment:
Participant gender:
Summary
A study to investigate the effects of GW679769 on sleep and cognition. Potential subjects
participate in a clinical screening visit and a two-night PSG recording session in the sleep
laboratory. Eligible subjects then participate in three separate two-night PSG sessions in
which they are randomized to receive placebo or one of two doses of GW679769 60 minutes prior
to bedtime, one treatment for each session in a balanced order. Each treatment session is
separated by a two-week drug-free period and occur on the same day of the week. A safety
follow-up visit occurs 2 weeks after the last treatment session.